1. A Cost-Consequence Analysis of Different Screening Procedures in Alzheimer’s Disease: Results from the MOPEAD Project
- Author
-
Wimo, Anders, Belger, Mark, Sannemann, Lena, Stoekenbroek, Malou, Gurruchaga Telleria, Miren, Valero, Sergi, Vermunt, Lisa, Waterink, Lisa, Winblad, Bengt, Visser, Peter Jelle, Zwan, Marissa, Boada, Mercè, Bon, Jaka, Collaborators, consortium, members of the MOPEAD, Escher, Claus, Müller, Theresa, Bogdanovic, Nenad, Andersen, Pia, Spulber, Gabriela, Sundström, Maria, Westman, Eric, Ferreira, Daniel, Jessen, Frank, Jelic, Vesna, Haglund, Anders, Stomrud, Erik, Nelvig, Anders, Saha, Samir, Petek, Davorina, Serné, Erik, Dumas, Annette, Kramberger, Milica G, Jamilis, Laura, Johansson, Gunilla, Rodrigo Salas, Adrián, Rodríguez Gómez, Octavio, Clinical chemistry, Neurology, and Amsterdam Neuroscience - Neurodegeneration
- Subjects
medicine.medical_specialty ,Referral ,statistics & numerical data [Internet] ,Cost consequences ,diagnosis ,Cost-Benefit Analysis ,Population ,costs ,Primary care ,Disease ,cost analysis ,Alzheimer Disease ,Diabetes mellitus ,medicine ,Diabetes Mellitus ,Dementia ,Humans ,Mass Screening ,ddc:610 ,education ,Screening procedures ,education.field_of_study ,Internet ,Primary Health Care ,business.industry ,General Neuroscience ,economics [Primary Health Care] ,screening ,diagnosis [Alzheimer Disease] ,General Medicine ,medicine.disease ,Europe ,Psychiatry and Mental health ,Clinical Psychology ,Family medicine ,cost-consequence analysis ,statistics & numerical data [Primary Health Care] ,diagnostic work-up ,Geriatrics and Gerontology ,Patient Participation ,business ,economics [Internet] ,Alzheimer’s disease ,Research Article ,dementia - Abstract
Background: For care planning and support, under-detection and late diagnosis of Alzheimer’s disease (AD) is a great challenge. Models of Patient-Engagement for Alzheimer’s Disease (MOPEAD) is an EU-funded project aiming at testing different strategies to improve this situation. Objective: To make a cost-consequence analysis of MOPEAD. Methods: Four screening strategies were tested in five countries (Germany, the Netherlands, Slovenia, Spain, and Sweden): 1) a web-approach; 2) Open-House initiative; 3) in primary care; and 4) by diabetes specialists. Persons-at-risk of AD in all strategies were offered referral to a hospital-based specialist. The primary health-economic outcome was the cost per true-positive case (TP) of AD from the screened population. Results: Of 2,847 screened persons, 1,121 screened positive (39%), 402 were evaluated at memory clinics (14%), and 236 got an AD diagnosis (8%). The cost per TP of those screened was €3,115 with the web-approach, €2,722 with the Open-House, €1,530 in primary care, and €1,190 by diabetes specialists. Sensitivity analyses that more likely reflect the real-world situation confirmed the results. The number-needed-to-screen was 30 with the web-approach, 8 with the Open-House and primary care, and 6 with the diabetes specialists. There were country differences in terms of screening rates, referrals to memory clinics, staff-types involved, and costs per TP. Conclusion: In primary care and by the diabetes specialist, the costs per TP/screened population were lowest, but the capacity of such settings to identify cases with AD-risk must be discussed. Hence new diagnostic strategies such as web-solutions and Open-House initiatives may be valuable after modifications.
- Published
- 2021
- Full Text
- View/download PDF